Rapport Therapeutics (RAPP) Institutional Ownership $18.46 +0.43 (+2.38%) (As of 01:48 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Rapport Therapeutics (NASDAQ:RAPP)Number ofInstitutional Buyers(last 12 months)22TotalInstitutional Inflows(last 12 months)$19.44MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$663.55K Get RAPP Insider Trade Alerts Want to know when executives and insiders are buying or selling Rapport Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RAPP Institutional Buying and Selling by Quarter Ad Insiders ExposedNo one’s talking about these Trump tradesAs you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Rapport Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC12,863$264K0.0%+36.8%0.035% 11/16/2024 Geode Capital Management LLC201,748$4.13M0.0%N/A0.552% 11/15/2024 Barclays PLC12,863$264K0.0%+36.8%0.035% 11/15/2024 State Street Corp58,046$1.19M0.0%N/A0.159% 11/15/2024 Maven Securities LTD29,930$613K0.0%N/A0.082% 11/14/2024 Eventide Asset Management LLC110,401$2.26M0.0%+120.8%0.302% Get the Latest News and Ratings for RAPP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/14/2024 Acuta Capital Partners LLC17,600$360K0.3%-12.0%0.048% 11/14/2024 MetLife Investment Management LLC5,710$117K0.0%N/A0.016% 11/13/2024 BNP Paribas Financial Markets1,684$34K0.0%N/A0.005% 11/13/2024 FMR LLC5,486,468$112.36M0.0%+10.1%14.999% 11/13/2024 The Manufacturers Life Insurance Company77,344$1.58M0.0%+2.4%0.211% 11/12/2024 Charles Schwab Investment Management Inc.73,146$1.50M0.0%N/A0.200% 11/7/2024 LMR Partners LLP20,000$410K0.0%-60.0%0.055% 10/23/2024 Values First Advisors Inc.1,507$31K0.0%N/A0.004% 10/3/2024 SG Americas Securities LLC4,934$101K0.0%N/A0.014% 8/27/2024 Logos Global Management LP208,910$4.86M0.4%N/A0.591% 8/16/2024 Perceptive Advisors LLC748,183$17.40M0.4%N/A2.045% 8/15/2024 The Manufacturers Life Insurance Company75,516$1.76M0.0%N/A0.206% 8/15/2024 Millennium Management LLC116,782$2.72M0.0%N/A0.319% 8/14/2024 Squarepoint Ops LLC16,345$380K0.0%N/A0.045% 8/14/2024 Sandia Investment Management LP5,000$116K0.2%N/A0.014% 8/14/2024 ARCH Venture Management LLC3,728,738$86.73M31.6%N/A10.193% 8/14/2024 Davidson Kempner Capital Management LP10,000$229K0.0%N/A0.027% 8/10/2024 Sofinnova Investments Inc.1,951,562$45.39M2.4%N/A5.516% 8/9/2024 Johnson & Johnson2,498,051$58.11M14.5%N/A7.061% 8/3/2024 TD Asset Management Inc101,522$2.36M0.0%N/A0.287% (Data available from 1/1/2016 forward) RAPP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RAPP shares? During the previous two years, 24 institutional investors and hedge funds held shares of Rapport Therapeutics. The most heavily invested institutionals were FMR LLC ($112.36M), ARCH Venture Management LLC ($86.73M), Johnson & Johnson ($58.11M), Sofinnova Investments Inc. ($45.39M), Perceptive Advisors LLC ($17.40M), Logos Global Management LP ($4.86M), and Geode Capital Management LLC ($4.13M).Learn more on RAPP's institutional investors. Which institutional investors have been buying Rapport Therapeutics stock? Of the 22 institutional investors that purchased Rapport Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ARCH Venture Management LLC ($3.73M), Johnson & Johnson ($2.50M), Sofinnova Investments Inc. ($1.95M), Perceptive Advisors LLC ($748.18K), FMR LLC ($503.12K), Logos Global Management LP ($208.91K), and Geode Capital Management LLC ($201.75K). How much institutional buying is happening at Rapport Therapeutics? Institutional investors have bought a total of 10,409,586 shares in the last 24 months. This purchase volume represents approximately $19.44M in transactions. Which Rapport Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Rapport Therapeutics stock in the last 24 months: LMR Partners LLP ($30K), and Acuta Capital Partners LLC ($2.40K). How much institutional selling is happening at Rapport Therapeutics? Institutional investors have sold a total of 32,400 shares in the last 24 months. This volume of shares sold represents approximately $663.55K in transactions. Related Companies CPRX Institutional Ownership HCM Institutional Ownership ARWR Institutional Ownership DYN Institutional Ownership PTGX Institutional Ownership AMRX Institutional Ownership NAMS Institutional Ownership LBPH Institutional Ownership CNTA Institutional Ownership IOVA Institutional Ownership This page (NASDAQ:RAPP) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
